Clinical Trial Update: Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a monoclonal antibody in combination with chemotherapy for metastatic HER2-overexpressing breast cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Monoclonal antibody plus chemotherapy (unspecified)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED